Pulse Biosciences shares interim thyroid nodule study outcomes
Pulse Biosciences released six‑month interim data from its PRECISE‑BTN trial of the nPulse Vybrance system for benign thyroid nodules. In the 43‑patient cohort that reached the six‑month mark, 86% met the primary endpoint of at least a half reduction in nodule size, and the median shrinkage was 72%. Patients also reported a 78% improvement in quality‑of‑life scores and an 82% rate of complete relief from neck pressure or fullness, with no serious adverse events recorded. The company said full‑cohort results will be presented at six and twelve months.
Why it matters
The interim efficacy signals suggest the device could become a non‑surgical option for thyroid nodules, potentially expanding the market for minimally invasive treatments. Investors should watch for the final data release, which may affect the company's revenue outlook and valuation.
Key facts
- 1The interim analysis covered 43 patients who had reached the six‑month assessment. investing.com
- 286% of those patients achieved at least a 50% reduction in nodule volume at six months. investing.com
- 3The median reduction in nodule volume was 72% at the six‑month point. investing.com
- 4ThyPRO‑39 quality‑of‑life scores improved by 78% from baseline. investing.com
- 5Among participants with baseline neck pressure or fullness, 82% reported full symptom resolution. investing.com
- 6No serious adverse events were reported in the interim cohort. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.